Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Down 64.0% in February

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) was the target of a significant decline in short interest during the month of February. As of February 13th, there was short interest totaling 81,117 shares, a decline of 64.0% from the January 29th total of 225,242 shares. Based on an average daily volume of 182,528 shares, the short-interest ratio is currently 0.4 days. Approximately 0.6% of the shares of the company are sold short. Approximately 0.6% of the shares of the company are sold short. Based on an average daily volume of 182,528 shares, the short-interest ratio is currently 0.4 days.

Hedge Funds Weigh In On Genenta Science

A number of institutional investors have recently added to or reduced their stakes in GNTA. SmartHarvest Portfolios LLC purchased a new stake in shares of Genenta Science in the 4th quarter valued at $26,000. Citadel Advisors LLC purchased a new stake in Genenta Science during the third quarter valued at about $41,000. Alyeska Investment Group L.P. bought a new position in shares of Genenta Science during the fourth quarter valued at about $328,000. Norges Bank purchased a new position in shares of Genenta Science in the fourth quarter worth about $337,000. Finally, Weiss Asset Management LP bought a new stake in shares of Genenta Science in the 4th quarter valued at about $480,000. 15.13% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genenta Science in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Genenta Science Stock Up 3.2%

GNTA stock traded up $0.03 during mid-day trading on Friday, reaching $0.99. 44,555 shares of the company traded hands, compared to its average volume of 1,619,263. The company has a fifty day moving average price of $1.20 and a 200-day moving average price of $2.26. Genenta Science has a 52-week low of $0.71 and a 52-week high of $10.00.

Genenta Science (NASDAQ:GNTA) last released its quarterly earnings data on Friday, October 10th. The company reported ($0.10) EPS for the quarter. On average, equities analysts predict that Genenta Science will post -0.93 EPS for the current fiscal year.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.